OPK logo

OPKO Health (OPK) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

02 November 1995

Indexes:

Not included

Description:

OPKO Health is a biotechnology and pharmaceutical company that focuses on developing innovative medical products and diagnostics. They work on treatments for various diseases and provide advanced laboratory services. OPKO aims to improve healthcare through research, technology, and partnerships in the medical field.

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

08 Nov '24 Barrington Research
Outperform
26 Sept '24 HC Wainwright & Co.
Buy
20 Sept '24 Barrington Research
Outperform
17 Sept '24 Piper Sandler
Overweight
17 Sept '24 HC Wainwright & Co.
Buy
08 Aug '24 Barrington Research
Outperform
18 July '24 Piper Sandler
Overweight
08 May '24 HC Wainwright & Co.
Buy
03 Apr '24 HC Wainwright & Co.
Buy
01 Apr '24 Piper Sandler
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
OPK
zacks.com08 November 2024

Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.

OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPK
zacks.com07 November 2024

OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.11 per share a year ago.

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
OPK
zacks.com11 October 2024

OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
OPK
globenewswire.com07 October 2024

WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS).

Here's Why You Should Retain OPKO Health Stock in Your Portfolio
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK
zacks.com02 October 2024

OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.

OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
OPK
zacks.com08 August 2024

Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.

Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
OPK
zacks.com06 June 2024

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
OPK
Zacks Investment Research01 April 2024

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPK
Zacks Investment Research25 March 2024

OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.

OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
OPK
Zacks Investment Research28 February 2024

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

FAQ

  • What is the primary business of OPKO Health?
  • What is the ticker symbol for OPKO Health?
  • Does OPKO Health pay dividends?
  • What sector is OPKO Health in?
  • What industry is OPKO Health in?
  • What country is OPKO Health based in?
  • When did OPKO Health go public?
  • Is OPKO Health in the S&P 500?
  • Is OPKO Health in the NASDAQ 100?
  • Is OPKO Health in the Dow Jones?
  • When was OPKO Health's last earnings report?
  • When does OPKO Health report earnings?
  • Should I buy OPKO Health stock now?

What is the primary business of OPKO Health?

OPKO Health is a biotechnology and pharmaceutical company that focuses on developing innovative medical products and diagnostics. They work on treatments for various diseases and provide advanced laboratory services. OPKO aims to improve healthcare through research, technology, and partnerships in the medical field.

What is the ticker symbol for OPKO Health?

The ticker symbol for OPKO Health is NASDAQ:OPK

Does OPKO Health pay dividends?

No, OPKO Health does not pay dividends

What sector is OPKO Health in?

OPKO Health is in the Healthcare sector

What industry is OPKO Health in?

OPKO Health is in the Diagnostics & Research industry

What country is OPKO Health based in?

OPKO Health is headquartered in United States

When did OPKO Health go public?

OPKO Health's initial public offering (IPO) was on 02 November 1995

Is OPKO Health in the S&P 500?

No, OPKO Health is not included in the S&P 500 index

Is OPKO Health in the NASDAQ 100?

No, OPKO Health is not included in the NASDAQ 100 index

Is OPKO Health in the Dow Jones?

No, OPKO Health is not included in the Dow Jones index

When was OPKO Health's last earnings report?

OPKO Health's most recent earnings report was on 7 November 2024

When does OPKO Health report earnings?

The next expected earnings date for OPKO Health is 27 February 2025

Should I buy OPKO Health stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions